Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 3.
doi: 10.1002/psp4.13246. Online ahead of print.

A model-informed clinical trial simulation tool with a graphical user interface for Duchenne muscular dystrophy

Affiliations
Free article

A model-informed clinical trial simulation tool with a graphical user interface for Duchenne muscular dystrophy

Jongjin Kim et al. CPT Pharmacometrics Syst Pharmacol. .
Free article

Abstract

Quantitative model-based clinical trial simulation tools play a critical role in informing study designs through simulation before actual execution. These tools help drug developers explore various trial scenarios in silico to select a clinical trial design to detect therapeutic effects more efficiently, therefore reducing time, expense, and participants' burden. To increase the usability of the tools, user-friendly and interactive platforms should be developed to navigate various simulation scenarios. However, developing such tools challenges researchers, requiring expertise in modeling and interface development. This tutorial aims to address this gap by guiding developers in creating tailored R Shiny apps, using an example of a model-based clinical trial simulation tool that we developed for Duchenne muscular dystrophy (DMD). In this tutorial, the structural framework, essential controllers, and visualization techniques for analysis are described, along with key code examples such as criteria selection and power calculation. A virtual population was created using a machine learning algorithm to enlarge the available sample size to simulate clinical trial scenarios in the presented tool. In addition, external validation of the simulated outputs was conducted using a placebo arm of a recently published DMD trial. This tutorial will be particularly useful for developing clinical trial simulation tools based on DMD progression models for other end points and biomarkers. The presented strategies can also be applied to other diseases.

PubMed Disclaimer

References

REFERENCES

    1. U.S. Food and Drug Administration. Pediatric rare diseases – a collaborative approach for drug development using gaucher disease as a model; draft guidance for industry. Accessed September 25, 2024. https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents...
    1. U.S. Food and Drug Administration. Rare disease day 2020: FDA continues important work on treatments for rare diseases. Accessed September 25, 2024. https://www.fda.gov/news‐events/fda‐voices/rare‐disease‐day‐2020‐fda‐con...
    1. U.S. Food and Drug Administration. Medical products for rare diseases and conditions. Accessed September 25, 2024. https://www.fda.gov/industry/medical‐products‐rare‐diseases‐and‐conditions
    1. U.S. Food and Drug Administration. Rare Diseases Team. Accessed September 25, 2024. https://www.fda.gov/about‐fda/center‐drug‐evaluation‐and‐research‐cder/r...
    1. European Medicines Agency. Orphan designation: overview. Accessed September 25, 2024. https://www.ema.europa.eu/en/human‐regulatory‐overview/orphan‐designatio...

LinkOut - more resources